Details of the Drug

General Information of Drug (ID: DMRAP4S)

Drug Name

Acoramidis

Synonyms

Acoramidis; AG-10; Acoramidis [USAN]; AG10; 1446711-81-4; T12B44A1OE; 3-[3-(3,5-Dimethyl-1h-Pyrazol-4-Yl)propoxy]-4-Fluorobenzoic Acid; UNII-T12B44A1OE; CHEMBL3940890; 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid; WHO 11205; Benzoic acid, 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluoro-; 4hiq; ACORAMIDIS [INN]; ACORAMIDIS [WHO-DD]; SCHEMBL15816954; BDBM50197885; AKOS040759821; HY-109165; CS-0116350; E79901; Q27451739; 16V

Indication

Disease Entry	ICD 11	Status	REF
Transthyretin amyloid cardiomyopathy	5D00.20	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C15H17FN2O3
Canonical SMILES: CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F
InChI: InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20)
InChIKey: WBFUHHBPNXWNCC-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 71464713
TTD ID: D5EHL4

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin (TTR)	TTC1I86	TTHY_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03860935) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of AstraZeneca